These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3324381)

  • 21. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor.
    Bertelé V; Falanga A; Tomasiak M; Cerletti C; de Gaetano G
    Thromb Haemost; 1984 Feb; 51(1):125-8. PubMed ID: 6326343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat.
    Maguire ED; Wallis RB
    Thromb Res; 1983 Oct; 32(1):15-27. PubMed ID: 6689221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of platelet thromboxane synthetase by 1-(3-benzyloxy-1[E]octenyl)imidazole.
    Sincholle D; Coquelet C; Bonne C
    Arzneimittelforschung; 1986; 36(1):117-9. PubMed ID: 3082339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thromboxane synthetase inhibition as antithrombotic strategy.
    Vermylen J; Defreyn G; Carreras LO; Machin SJ; Van Schaeren J; Verstraete M
    Lancet; 1981 May; 1(8229):1073-5. PubMed ID: 6112447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute arterial thrombosis in rabbits: reduced platelet accumulation after treatment with dazoxiben hydrochloride (UK 37,248-01).
    Randall MJ; Wilding RI
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):49S-55S. PubMed ID: 6687429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of dazoxiben on platelet-vessel wall interaction.
    Davies JA; Menys VC
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):45S-46S. PubMed ID: 6681703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2.
    Defreyn G; Deckmyn H; Vermylen J
    Thromb Res; 1982 Jun; 26(6):389-400. PubMed ID: 7051416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of thromboxane synthetase inhibition on platelet function and morphology during ovine pregnancy-induced hypertension.
    Miller KW; Keith JC
    Thromb Haemost; 1988 Dec; 60(3):365-71. PubMed ID: 3238644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of dazoxiben, an inhibitor of thromboxane synthetase, on forearm vasoconstriction in response to cold stimulation, and on human blood vessel prostacyclin production.
    Cowley AJ; Jones EW; Hanley SP
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):107S-112S. PubMed ID: 6337600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations.
    Vermylen J; Deckmyn H
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):17S-22S. PubMed ID: 6297527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mechanism of anti-thrombotic, thrombolytic and fibrinolytic actions of camonagrel--a new thromboxane synthase inhibitor.
    Gryglewski RJ; Szczeklik A; Korbut R; Swies J; Musiał J; Krzanowski M; Maga P
    Wien Klin Wochenschr; 1995; 107(9):283-9. PubMed ID: 7778318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A paradox of thrombogenesis by streptokinase and its prevention by iloprost and camonagrel.
    Korbut R; Gryglewski RJ
    Methods Find Exp Clin Pharmacol; 1996 Apr; 18(3):167-74. PubMed ID: 8738067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacology of thromboxane synthetase inhibitors.
    Smith JB
    Fed Proc; 1987 Jan; 46(1):139-43. PubMed ID: 3542573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of thromboxane biosynthesis in splanchnic ischemia shock.
    Oei HH; Zoganas HC; Sakane Y; Robson RD; Glenn TM
    Circ Shock; 1986; 18(2):95-106. PubMed ID: 3753907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom.
    Deckmyn H; Van Houtte E; Verstraete M; Vermylen J
    Biochem Pharmacol; 1983 Sep; 32(18):2757-62. PubMed ID: 6578796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
    Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
    Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
    Aiken JW; Shebuski RJ; Miller OV; Gorman RR
    J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of thromboxane and 12-HPETE formation by dazoxiben and its two thiophenic acid-substituted derivatives.
    Smith EF; Darius H; Ferber H; Schrör K
    Eur J Pharmacol; 1985 Jun; 112(2):161-9. PubMed ID: 3896821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.